author-photo

M. Mehta

Takeda Pharmaceutical Company

4

Papers

3

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

FP09.02 Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
FP09.01 Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.

2021 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (3)